Chimeric Therapeutics Limited (ASX:CHM)
Australia
· Delayed Price · Currency is AUD 0.0020
0.00 (0.00%)
Mar 9, 2026, 2:52 PM AEST
Chimeric Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 |
| Operating Revenue | 3.97 | 3.97 | - | - | - | - | Upgrade
|
| Other Revenue | 5.78 | 8.72 | 7.46 | 4.51 | 2.62 | - | Upgrade
|
| Revenue | 9.75 | 12.68 | 7.46 | 4.51 | 2.62 | - | Upgrade
|
| Revenue Growth (YoY) | 377.63% | 70.09% | 65.52% | 72.16% | - | - | Upgrade
|
| Cost of Revenue | 0.85 | 0.85 | - | - | - | - | Upgrade
|
| Gross Profit | 8.9 | 11.84 | 7.46 | 4.51 | 2.62 | - | Upgrade
|
| Selling, General & Admin | 5.79 | 6.45 | 9 | 11.73 | 7.9 | 8.97 | Upgrade
|
| Research & Development | 7.64 | 10.79 | 10.19 | 14.43 | 6.12 | 3.78 | Upgrade
|
| Operating Expenses | 14.21 | 18.33 | 19.76 | 29.49 | 17.19 | 14.85 | Upgrade
|
| Operating Income | -5.31 | -6.49 | -12.31 | -24.98 | -14.57 | -14.85 | Upgrade
|
| Interest Expense | -0.3 | -0.21 | -0.33 | -0.77 | -0.64 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.05 | 0.05 | 0.12 | 0.03 | 0.01 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.11 | -0.11 | 0.06 | -0.09 | -0.53 | -0.26 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0.9 | - | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | -5.68 | -6.77 | -11.56 | -25.82 | -15.73 | -15.11 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0 | -0 | -0 | -0 | -0 | - | Upgrade
|
| Other Unusual Items | -3.34 | -3.55 | -0.96 | - | - | - | Upgrade
|
| Pretax Income | -18.77 | -10.32 | -12.52 | -25.82 | -15.73 | -15.11 | Upgrade
|
| Income Tax Expense | 0.02 | 0.11 | 0.01 | 0.09 | 0.16 | - | Upgrade
|
| Net Income | -18.79 | -10.43 | -12.53 | -25.92 | -15.9 | -15.11 | Upgrade
|
| Net Income to Common | -18.79 | -10.43 | -12.53 | -25.92 | -15.9 | -15.11 | Upgrade
|
| Shares Outstanding (Basic) | 2,491 | 1,352 | 696 | 433 | 360 | 182 | Upgrade
|
| Shares Outstanding (Diluted) | 2,491 | 1,352 | 696 | 433 | 360 | 182 | Upgrade
|
| Shares Change (YoY) | 168.67% | 94.34% | 60.57% | 20.37% | 97.88% | - | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | -0.02 | -0.06 | -0.04 | -0.08 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | -0.02 | -0.06 | -0.04 | -0.08 | Upgrade
|
| Free Cash Flow | -8.49 | -7.28 | -7.54 | -16.31 | -13.17 | -8.85 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.01 | -0.04 | -0.04 | -0.05 | Upgrade
|
| Gross Margin | 91.31% | 93.32% | 100.00% | 100.00% | 100.00% | - | Upgrade
|
| Operating Margin | -54.44% | -51.14% | -165.01% | -554.44% | -556.82% | - | Upgrade
|
| Profit Margin | -192.71% | -82.23% | -168.01% | -575.20% | -607.48% | - | Upgrade
|
| Free Cash Flow Margin | -87.11% | -57.36% | -101.07% | -361.89% | -503.04% | - | Upgrade
|
| EBITDA | -4.28 | -5.46 | -11.22 | -24.02 | -13.62 | -14 | Upgrade
|
| EBITDA Margin | -43.86% | -43.01% | -150.50% | - | - | - | Upgrade
|
| D&A For EBITDA | 1.03 | 1.03 | 1.08 | 0.97 | 0.95 | 0.85 | Upgrade
|
| EBIT | -5.31 | -6.49 | -12.31 | -24.98 | -14.57 | -14.85 | Upgrade
|
| EBIT Margin | -54.44% | -51.14% | -165.01% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.